Company profile
www.oxfordbiotherapeutics.com
OxfordBioTherapeutics
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
CS01 | Transaction MzUyNjAzMDkyOWFkaXF6a2N4
Published 09 Jun 2026 11:55
PSC05 | Transaction MzUyNTkzMjY3OWFkaXF6a2N4
Published 08 Jun 2026 16:50
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNjgzNTA5NWFkaXF6a2N4
Published 23 Sep 2024 11:27
SH01 | Transaction MzQzNjIxMjA2OWFkaXF6a2N4
Published 17 Sep 2024 13:31
Company registered at Companies House
1 Apr 2007 to 31 Mar 2010
To establish a hepatotoxicity biomarker database in zebrafish embryos (ZFEs) using compounds with known toxicities. To use this database in parallel with OGeS''s existing OGAP database to select and validate potential drug safety protein biomarkers in both ZFEs and rodents (and ultimately, man). To develop highthroughput Ordered Peptide Array (OPA) screen...
